ARS Pharmaceuticals (SPRY) Competitors

ADMA Biologics (NASDAQ:ADMA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Does the MarketBeat Community favor ADMA or SPRY?

ADMA Biologics received 390 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 86.21% of users gave ARS Pharmaceuticals an outperform vote while only 72.05% of users gave ADMA Biologics an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 415 72.05%	Underperform Votes 161 27.95%
ARS Pharmaceuticals	Outperform Votes 25 86.21%	Underperform Votes 4 13.79%

Which has better valuation and earnings, ADMA or SPRY?

ADMA Biologics has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$459.38M	10.62	-$28.24M	$0.85	24.05
ARS Pharmaceuticals	$97.12M	14.49	-$54.37M	-$0.16	-89.56

Is ADMA or SPRY more profitable?

ADMA Biologics has a net margin of 17.80% compared to ARS Pharmaceuticals' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	17.80%	53.20%	26.07%
ARS Pharmaceuticals	N/A	-22.56%	-21.82%

Do insiders and institutionals hold more shares of ADMA or SPRY?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, ADMA or SPRY?

ADMA Biologics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Do analysts recommend ADMA or SPRY?

ADMA Biologics currently has a consensus target price of $24.25, indicating a potential upside of 18.64%. ARS Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 116.33%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Does the media favor ADMA or SPRY?

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than ADMA Biologics. MarketBeat recorded 28 mentions for ARS Pharmaceuticals and 13 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.29 beat ARS Pharmaceuticals' score of 0.43 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats ARS Pharmaceuticals on 11 of the 18 factors compared between the two stocks.